Real-world Burden Of Transthyretin Amyloid Cardiomyopathy Disease And Outcomes In Patients On Tafamidis Before Switching To Acoramidis [Poster no. 484]
Richard Wright1, Lily K. Stern2, Justin L. Grodin3, Fei Tang4, Michelle VanTieghem4, Elizabeth Nagelhout4, Allison Keshishian4, Bret Zeldow4, Liana Hennum5, Margarita Udall5, Daniel P. Judge6. 1Pacific Heart Institute, Santa Monica, CA; 2Cedars-Sinai Medical Center, Smidt Heart Institute, Beverly Hills, CA; 3The University of Texas Southwestern Medical Center, Dallas, TX; 4Genesis Research Group, Hoboken, NJ; 5BridgeBio Pharma, Inc., San Francisco, CA; 6Medical University of South Carolina, Charleston, SC
